REG - Cizzle Biotechnology - New Research Agreement with the University of York

Cizzle Biotechnology HoldingsAnnouncement

24/04/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230424:nRSX1358Xa&default-theme=true

RNS Number : 1358X  Cizzle Biotechnology Holdings PLC  24 April 2023

24 April 2023

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

 

New Research Agreement with the University of York for Cancer Diagnosis and Therapy

 

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to
announce that following successful results from its current research programme
with the University of York, due to end this year, that it has today signed a
new research agreement with the University for the further development and
validation of its CIZ 1B biomarker technology for early stage cancer diagnosis
and other potential applications in cancer therapy.

This includes the evaluation of the Company's proprietary biomarker for
detecting a range of cancers in addition to the existing programme for early
lung cancer detection.

 

Highlights

 

 ·         New 12-month research and development agreement with the University of York
 ·         Builds on successful outcomes of current research programme on meeting key
           milestones for monoclonal antibody characterization and assay platform
           optimization
 ·         All intellectual property rights arising from the work to be owned by the
           Company
 ·         Extends access to state of the art facilities and world leading scientists to
           support new solutions for early cancer diagnostics and therapeutic tools

 

This new agreement will extend the work being conducted at the university
until 25th September 2024 and follows the successful programme initially
announced on 17 September 2021 and further extended to June 2023. With a focus
on the development and validation of molecular tools with potential
application in cancer diagnosis or therapy, significant progress has been made
in characterising and optimizing the company's antibodies for use and scale up
into the configuration required for further clinical trials ahead of the
launch of commercial early stage lung cancer assays. As in previous
agreements, Cizzle Biotechnology will own all intellectual property rights
arising from the work which strengthens the Company's position in creating new
solutions for early cancer diagnostics and therapeutic tools.

 

Cizzle Biotechnology was a spin out from the University of York based on
research and development by Professor Dawn Coverley at the University and the
first company from the university to be listed on the London Stock Exchange.
The company has a proven and long-term commitment to work with the University
of York which provides access to its leading-edge research facilities and
expertise.

 

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "I
am delighted to further extend our relationship with the University of York
and in particular the leading-edge research being a carried out in Professor
Dawn Coverley's laboratories. The continuity and commitment of the researchers
at the University has been a key building block in the development and
commercialization of the CIZ1B biomarker for early cancer diagnosis. The
current research programme has met some critical milestones, especially in
optimising the platform and antibodies required to scale up and bring to
market our diagnostic tests for early stage cancer detection. This new
agreement will continue our access to state of the art research facilities and
world leading scientists as we pursue our plans to bring early detection tests
for lung cancer and potentially other forms of cancer."

Enquiries:
 
 Cizzle Biotechnology Holdings plc                        Via IFC Advisory

 Allan Syms (Executive Chairman)

 Allenby Capital Limited                                  +44(0) 20 33285656

 John Depasquale

 Alex Brearley

 Novum Securities Limited                                 +44(0) 20 7399 9400

 Colin Rowbury

 Jon Bellis

 IFC Advisory Limited                                     +44(0) 20 3934 6630

 Tim Metcalfe

 Florence Chandler

 

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer. Cizzle Biotechnology is a spin- out from the University of York,
founded in 2006 around the work of Professor Coverley and colleagues. Its
proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early stage lung cancer.

For more information please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCITMMTMTJTTMJ